Skip to main content
SpringerLink
Log in

Anal Canal Cancer: Pathophysiology, Diagnosis and Treatment

  • Chapter
International Manual of Oncology Practice

  • 1308 Accesses

Abstract

Anal cancer is a rare malignancy accounting for 2.5 % of all digestive system malignancies in the United States. Squamous cell carcinoma is the most common histological variant comprising of 80–90 % of all anal cancer cases. Spread is by local extension and lymphatic pathways. The size of primary tumor and lymph node metastasis are the most important prognostic indicators. The primary goal of treatment is eradication of tumor with organ preservation. Abdomino-perineal resection with permanent end-colostomy, which was the standard definitive treatment for anal canal cancer in the past, is now reserved for residual or recurrent cancer. Combined modality treatment (CMT) comprising of radiotherapy and chemotherapy to preserve sphincter function is the preferred standard therapy for treatment of anal cancer. Chemoradiation itself has undergone remarkable development in the bygone years and various trials have determined the optimal radiation dose, fractionation and chemotherapeutic regimen. Definitive chemoradiation with concurrent 5-fluorouracil and Mitomycin-C is the established treatment in patients with anal cancer as confirmed by various trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Glynne-Jones R, Northover JM, Cervantes A, ESMO Guidelines Working Group (2010) Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v87–v92

    Article  PubMed  Google Scholar 

  2. Welton ML, Sharkey FE, Kahlenberg MS (2004) The etiology and epidemiology of anal cancer. Surg Oncol Clin N Am 13:263–275

    Article  PubMed  Google Scholar 

  3. Uronis HE, Bendell JC (2007) Anal cancer: an overview. Oncologist 12:524–534

    Article  PubMed  Google Scholar 

  4. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA et al (2004) Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101:270–280

    Article  PubMed  Google Scholar 

  5. Frisch M, Olsen JH, Bautz A, Melbye M (1994) Benign anal lesions and the risk of anal cancer. N Engl J Med 331:300–302

    Article  PubMed  CAS  Google Scholar 

  6. Frisch M, Johansen C (2000) Anal carcinoma in inflammatory bowel disease. Br J Cancer 83:89–90

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  7. Fenger C, Frisch M, Marti MC, Parc R (2000) Tumors of the anal canal. In: Hamilton SR, Aaltonen LA (eds) WHO classification of tumors, volume 2: pathology and genetics. Tumors of the digestive system. IARC Press, Lyon, pp 145–155

    Google Scholar 

  8. Welton ML, Lambert R, Bosman FT (2010) Tumors of the anal canal. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumors of the digestive system. IARC, Lyon, pp 183–193

    Google Scholar 

  9. Wietfeldt ED, Thiele J (2009) Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg 22:127–135

    Article  PubMed Central  PubMed  Google Scholar 

  10. Fenger C (1991) Anal neoplasia and its precursors: facts and controversies. Semin Diagn Pathol 8:190–201

    PubMed  CAS  Google Scholar 

  11. Myerson RJ, Karnell LH, Menck HR (1997) The national cancer data base report on carcinoma of the anus. Cancer 80:805–815

    Article  PubMed  CAS  Google Scholar 

  12. Boman BM, Moertel CG, O’Connell MJ, Scott M, Weiland LH, Beart RW et al (1984) Carcinoma of the anal canal: a clinical and pathological study of 188 cases. Cancer 54:114–125

    Article  PubMed  CAS  Google Scholar 

  13. Frost DB, Richards PC, Montague ED, Giacco GG, Martin RG (1984) Epidermoid cancer of the anorectum. Cancer 53:1285–1293

    Article  PubMed  CAS  Google Scholar 

  14. Gerard JP, Chapet O, Samiei F, Morignat E, Isaac S, Paulin C et al (2001) Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature. Cancer 92:77–84

    Article  PubMed  CAS  Google Scholar 

  15. Salmon RJ, Fenton J, Asselain B, Mathieu G, Girodet J, Durand JC et al (1984) Treatment of epidermoid anal canal cancer. Am J Surg 147:43–48

    Article  PubMed  CAS  Google Scholar 

  16. Papillon J, Montbarbon JF (1987) Epidermoid carcinoma of the anal canal. A series of 276 cases. Dis Colon Rectum 30:324–333

    Article  PubMed  CAS  Google Scholar 

  17. Stearns MW Jr, Urmacher C, Sternberg SS, Woodruff J, Attiyeh F (1980) Cancer of the anal canal. Curr Probl Cancer 4:1–44

    Article  PubMed  Google Scholar 

  18. Greenall MJ, Quan SH, Urmacher C et al (1985) Treatment of epidermoid carcinoma of the anal canal. Surg Gynecol Obstet 161:509–517

    PubMed  CAS  Google Scholar 

  19. Cummings BJ (2006) Metastatic anal cancer: the search for cure. Onkologie 29:5–6

    Article  PubMed  Google Scholar 

  20. Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A et al (2014) Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol 111:330–339

    Article  PubMed  Google Scholar 

  21. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging handbook, 7th edn. Springer, New York, pp 165–173

    Google Scholar 

  22. Das P, Crane CH, Eng C, Ajani JA (2008) Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res 2:10–14

    PubMed Central  PubMed  Google Scholar 

  23. Kim KH, Chang JS, Keum KC, Ahn JB, Lee CG, Koom WS (2013) Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience. Radiat Oncol J 31:25–33

    Article  PubMed Central  PubMed  Google Scholar 

  24. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 15:2040–2049

    PubMed  CAS  Google Scholar 

  25. Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr et al (2008) Fluorouracil, mitomycin, and radiotherapy vs. fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299:1914–1921

    Article  PubMed  CAS  Google Scholar 

  26. Glynne-Jones R, Sebag-Montefiore D, Adams R, Gollins S, Harrison M, Meadows HM et al (2013) Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer 119:748–755

    Article  PubMed  CAS  Google Scholar 

  27. Dougherty BG, Evans HL (1985) Carcinoma of the anal canal: a study of 79 cases. Am J Clin Pathol 83:159–164

    PubMed  CAS  Google Scholar 

  28. Nigro ND, Vaitkevicius VK, Considine B Jr (1974) Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 17:354–356

    Article  PubMed  CAS  Google Scholar 

  29. (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR anal cancer trial working party. UK co-ordinating committee on cancer research. Lancet 348:1049–1054

    Google Scholar 

  30. Northover J, Glynne-Jones R, Sebag-Montefiore D, James R, Meadows H, Wan S et al (2010) Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 102:1123–1128

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  31. Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S et al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14:2527–2539

    PubMed  CAS  Google Scholar 

  32. James R, Wan S, Glynne-Jones R, Sebag-Montefiore D, Kadalayil L, Northover J et al (2009) A randomized trial of CRT using mitomycinorcisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus. J Clin Oncol (Proc ASCO) 27(18suppl):abstr LBA-4009

    Google Scholar 

  33. Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB 3rd et al (2012) Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol 30:4344–4351

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  34. Peiffert D, Tournier-Rangeard L, Gérard JP, Lemanski C, François E, Giovannini M et al (2012) Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol 30:1941–1948

    Article  PubMed  CAS  Google Scholar 

  35. Deutsch E, Lemanski C, Pignon JP, Levy A, Delarochefordiere A, Martel-Lafay I et al (2013) Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. Ann Oncol 24:2834–2838

    Article  PubMed  CAS  Google Scholar 

  36. Levy A, Azria D, Pignon JP, Delarochefordiere A, Martel-Lafay I, Rio E et al (2015) Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial. Radiother Oncol 114:415–416

    Article  PubMed  Google Scholar 

  37. Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S et al (2012) Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys 83:1455–1462

    Article  PubMed  Google Scholar 

  38. Ortholan C, Resbeut M, Hannoun-Levi JM, Teissier E, Gerard JP, Ronchin P et al (2012) Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study). Int J Radiat Oncol Biol Phys 82:1988–1995

    Article  PubMed  Google Scholar 

  39. Weber DC, Kurtz JM, Allal AS (2001) The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 50:675–680

    Article  PubMed  CAS  Google Scholar 

  40. Graf R, Wust P, Hildebrandt B, Gögler H, Ullrich R, Herrmann R et al (2003) Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology 65:14–22

    Article  PubMed  CAS  Google Scholar 

  41. Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Houry S, Gallot D et al (2003) Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys 56:1259–1273

    Article  PubMed  Google Scholar 

  42. Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA et al (2011) Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 117:3342–3351

    Article  PubMed  Google Scholar 

  43. Konski A, Garcia M Jr, John M, Krieg R, Pinover W, Myerson R et al (2008) Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 72:114–118

    Article  PubMed Central  PubMed  Google Scholar 

  44. Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, DeLaney TF (1997) Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 39:651–657

    Article  PubMed  CAS  Google Scholar 

  45. Meyer A, Meier ZuEissen J, Karstens JH, Bremer M (2006) Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome. Acta Oncol 45:728–735

    Article  PubMed  Google Scholar 

  46. Menkarios C, Azria D, Laliberté B, Moscardo CL, Gourgou S, Lemanski C et al (2007) Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol 2:41

    Article  PubMed Central  PubMed  Google Scholar 

  47. Chen YJ, Liu A, Tsai PT, Vora NL, Pezner RD, Schultheiss TE et al (2005) Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes. Int J Radiat Oncol Biol Phys 63:274–281

    Article  PubMed  Google Scholar 

  48. Brooks CJ, Lee YK, Aitken K, Hansen VN, Tait DM, Hawkins MA (2013) Organ-sparing intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans. Clin Oncol (R Coll Radiol) 25:155–161

    Article  CAS  Google Scholar 

  49. Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL et al (2012) Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys 82:153–158

    Article  PubMed  Google Scholar 

  50. Pepek JM, Willett CG, Wu QJ, Yoo S, Clough RW, Czito BG (2010) Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys 78:1413–1419

    Article  PubMed  Google Scholar 

  51. DeFoe SG, Beriwal S, Jones H, Rakfal S, Heron DE, Kabolizadeh P et al (2012) Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma – clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clin Oncol (R Coll Radiol) 24:424–431

    Article  CAS  Google Scholar 

  52. Kachnic LA, Winter K, Myerson RJ, Goodyear MD, Willins J, Esthappan J et al (2013) RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-c for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 86:27–33

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  53. Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR et al (2009) Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys 74:824–830

    Article  PubMed Central  PubMed  Google Scholar 

  54. Mazeron JJ, van Limbergen E (2000) Anorectal cancer. In: Gerbaulet A, Pötter R, Mazeron J, Meertens H, VanLimbergen E (eds) The GECESTRO handbook of brachytherapy. ESTRO, Brussels, pp 505–514

    Google Scholar 

  55. Delclos L (1982) A second look at interstitial irradiation. In: Deeley TJ (ed) Topical reviews in radiotherapy and oncology, 2nd edn. John Wright & Sons, London

    Google Scholar 

  56. Glynne-Jones R, James R, Meadows H, Begum R, Cunningham D, Northover J et al (2012) Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin C (MMC) or cisplatin (CisP) with or without maintenance CisP/FU in squamous cell carcinoma of the anus: results of ACT II. J Clin Oncol 30(Suppl):Abstr 4004

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiotherapy & Oncology, GMCH, 160030, Chandigarh, India

    Divya Khosla (Assistant Professor)

  2. Senior Consultant, Department of Gastroenterology, Silver Oaks Hospital, 160062, Mohalli, India

    Rahul Gupta

Authors
  1. Divya Khosla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rahul Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Divya Khosla .

Editor information

Editors and Affiliations

  1. Medical Oncology, University of Algarve, Faro, Portugal

    Ramon Andrade de Mello

  2. edificio 7, ala nascente, 3º andar, University of Algarve, Dept Cie Biomed edificio 7, ala nascente, 3º andar, Faro, Portugal

    Álvaro Tavares

  3. Medical Oncology, University of Athens, Athens, Greece

    Giannis Mountzios

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Khosla, D., Gupta, R. (2015). Anal Canal Cancer: Pathophysiology, Diagnosis and Treatment. In: de Mello, R., Tavares, Á., Mountzios, G. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-21683-6_14

Download citation

Publish with us

Policies and ethics

Search

Navigation